Differences in antimicrobial resistance gene abundance and microbial diversity of the gut microbiome in patients on antibiotics enrolled in a clinical trial.

IF 3.4 Q2 INFECTIOUS DISEASES
Therapeutic Advances in Infectious Disease Pub Date : 2025-06-05 eCollection Date: 2025-01-01 DOI:10.1177/20499361251337597
Adam G Stewart, Patrick N A Harris, Rikki M A Graham, Amy V Jennison, Sanmarie Schlebusch, Asha Kakkanat, Tiffany Harris-Brown, David L Paterson, Brian M Forde
{"title":"Differences in antimicrobial resistance gene abundance and microbial diversity of the gut microbiome in patients on antibiotics enrolled in a clinical trial.","authors":"Adam G Stewart, Patrick N A Harris, Rikki M A Graham, Amy V Jennison, Sanmarie Schlebusch, Asha Kakkanat, Tiffany Harris-Brown, David L Paterson, Brian M Forde","doi":"10.1177/20499361251337597","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Understanding how the gut microbiome adapts on exposure to individual antibiotics, with respect to antimicrobial resistance gene (ARG) enrichment, is important.</p><p><strong>Objectives: </strong>To characterise the changes that occur in the gut microbiome of patients enrolled in an antibiotic clinical trial and to propose methods in which to embed gut microbiome analysis into clinical trials.</p><p><strong>Design: </strong>This was a prospective cohort study of hospitalised patients who were successfully enrolled and randomised into two clinical trials between January 2021 to December 2021.</p><p><strong>Methods: </strong>Adult patients admitted to the hospital with a bloodstream infection have been randomised to receive either benzylpenicillin, ampicillin, cefazolin, ceftriaxone, piperacillin-tazobactam or meropenem at a single institution. Faecal specimens were collected at enrolment and every second day until discharge. Each specimen underwent DNA sequencing to determine microbial diversity and ARG abundance.</p><p><strong>Results: </strong>Ten patients (including six females) were included. DNA concentration and sampling quality were markedly lower for rectal swabs compared to stool samples. Relative abundance of <i>Enterococcus faecium</i> was increased in individual patients where treatment included ampicillin, meropenem and piperacillin-tazobactam. Piperacillin-tazobactam also increased the abundance of key beta-lactamase genes (<i>bla</i> <sub>SHV-100</sub>, <i>bla</i> <sub>OXA-392</sub>, <i>bla</i> <sub>CMY-18</sub>). Ampicillin increased the abundance of <i>bla</i> <sub>TEM-1A</sub>. There were no extended-spectrum beta-lactamase (ESBL) or carbapenemase genes detected in our study. The presence of key anaerobes such as <i>Clostridium</i> and <i>Bifidobacterium</i> species appeared to play an important role in colonisation resistance of <i>E. faecium</i> and <i>Clostridioides difficile</i>.</p><p><strong>Conclusion: </strong>Differential changes in anaerobic bacterial genera on exposure to antibiotics may be a key determinant of colonisation resistance. The pre-analytical phase of microbiome analysis is a critical factor in data quality and interpretation.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251337597"},"PeriodicalIF":3.4000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144387/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Infectious Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20499361251337597","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Understanding how the gut microbiome adapts on exposure to individual antibiotics, with respect to antimicrobial resistance gene (ARG) enrichment, is important.

Objectives: To characterise the changes that occur in the gut microbiome of patients enrolled in an antibiotic clinical trial and to propose methods in which to embed gut microbiome analysis into clinical trials.

Design: This was a prospective cohort study of hospitalised patients who were successfully enrolled and randomised into two clinical trials between January 2021 to December 2021.

Methods: Adult patients admitted to the hospital with a bloodstream infection have been randomised to receive either benzylpenicillin, ampicillin, cefazolin, ceftriaxone, piperacillin-tazobactam or meropenem at a single institution. Faecal specimens were collected at enrolment and every second day until discharge. Each specimen underwent DNA sequencing to determine microbial diversity and ARG abundance.

Results: Ten patients (including six females) were included. DNA concentration and sampling quality were markedly lower for rectal swabs compared to stool samples. Relative abundance of Enterococcus faecium was increased in individual patients where treatment included ampicillin, meropenem and piperacillin-tazobactam. Piperacillin-tazobactam also increased the abundance of key beta-lactamase genes (bla SHV-100, bla OXA-392, bla CMY-18). Ampicillin increased the abundance of bla TEM-1A. There were no extended-spectrum beta-lactamase (ESBL) or carbapenemase genes detected in our study. The presence of key anaerobes such as Clostridium and Bifidobacterium species appeared to play an important role in colonisation resistance of E. faecium and Clostridioides difficile.

Conclusion: Differential changes in anaerobic bacterial genera on exposure to antibiotics may be a key determinant of colonisation resistance. The pre-analytical phase of microbiome analysis is a critical factor in data quality and interpretation.

临床试验中抗生素患者肠道微生物组的耐药基因丰度和微生物多样性差异
背景:了解肠道微生物群如何适应暴露于单一抗生素,就抗菌耐药基因(ARG)的富集而言,是很重要的。目的:描述参加抗生素临床试验的患者肠道微生物组发生的变化,并提出将肠道微生物组分析纳入临床试验的方法。设计:这是一项前瞻性队列研究,入院患者在2021年1月至2021年12月期间成功入组并随机分为两组临床试验。方法:因血液感染入院的成年患者被随机分组,在单一机构接受青霉素、氨苄西林、头孢唑林、头孢曲松、哌拉西林-他唑巴坦或美罗培南治疗。在入组时和出院前每隔一天采集一次粪便标本。每个标本都进行了DNA测序,以确定微生物多样性和ARG丰度。结果:纳入10例患者,其中女性6例。与粪便样本相比,直肠拭子的DNA浓度和采样质量明显较低。在接受氨苄西林、美罗培南和哌拉西林-他唑巴坦治疗的个别患者中,粪肠球菌的相对丰度增加。哌拉西林-他唑巴坦还增加了关键β -内酰胺酶基因(bla SHV-100, bla OXA-392, bla CMY-18)的丰度。氨苄西林增加了bla TEM-1A的丰度。本研究未检测到广谱β -内酰胺酶(ESBL)或碳青霉烯酶基因。关键厌氧菌如梭状芽胞杆菌和双歧杆菌的存在似乎在粪肠杆菌和艰难梭状芽胞杆菌的定植抗性中起重要作用。结论:厌氧菌属在抗生素暴露下的差异变化可能是定植耐药性的关键决定因素。微生物组分析的分析前阶段是数据质量和解释的关键因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.30
自引率
8.80%
发文量
64
审稿时长
9 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信